About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Lymphatic Research and Biology

Editor-in-Chief: Stanley G. Rockson, MD

ISSN: 1539-6851 • Published Quarterly • Online ISSN: 1557-8585

Current Volume: 12

Latest Impact Factor* is 1.660

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Lymphatic Research and Biology is a quarterly, peer-reviewed journal which will provide an interdisciplinary forum for the world’s leading biomedical investigators to discuss current and anticipated developments in lymphatic biology and pathology. 

    The Journal features fundamental scientific research of relevance to the lymphatic system and publishes original work from a variety of investigative disciplines, including genetics, biochemistry and biophysics, cellular and molecular biology, physiology and pharmacology, anatomy, developmental biology, and pathology. The Journal also encourages the submission of state-of-the-art reviews in focus areas such as vasculogenesis and angiogenesis, the genetics of lymphatic disorders, muscle cell biology, interstitial signaling mechanisms, and others.

     

    Each figure should be submitted in a separate TIFF or EPS file.  (See below.)   References must be part of the manuscript text and not embedded through a separate program, such as EndNote. Authors with questions should address them to the Editorial Office at (516) 625-9675 or by e-mail to journal@lymphaticresearch.org

    Manuscript Submission

    Manuscripts must be submitted online using the following URL:

     http://mc.manuscriptcentral.com/lymphatic

    Submissions should be formatted for US Letter paper (8.5 x11 inches). Authors should attempt to reduce file sizes to 1 megaByte or less. Manuscripts must contain title page, abstract, condensed abstract, text, tables, figure legends.

    General Instructions

    1. Manuscripts should be prepared in Microsoft Word. Manuscripts should be double-spaced.  Number the pages, including the title page. Leave 1-inch margins on all sides. Do not use justified margins.
    2. Cite references, figures, and tables in numeric order. If any material has been published previously (figures, tables, etc), provide written permission from the copyright holder to use such material.
    3. Consult the American Medical Association Manual of Style, 9th ed, Baltimore, MD, Williams; Wilkins, 1998, for style.
    4. Assemble the manuscript in this order: Title page, abstracts, text, acknowledgments, references, figure legends, tables, and figures.
    5. The title page (page 1) should contain these elements: Full title. Running title (not to exceed 50 characters,including spaces). Authors' names, academic degrees, and affiliations. Name and complete address for correspondence (include street name and address as well as PO box) and address for reprints if different from correspondence. Fax number, telephone number, and E-mail address. Sources of support that require acknowledgment.

    Abstract

    Please supply a structured abstract of not more than 250 words, which should be self-explanatory without reference to the text. Do not cite references in the abstract. Limit use of acronyms and abbreviations. Define at first use with acronym or abbreviation in parentheses. Use the following headings: Background (rationale for study), Methods and Results (brief presentation of methods and presentation of significant results; note that both categories are included under one heading), and Conclusions (succinct statement of data interpretation). Include a condensed abstract of not more than 100 words for use in the annotated table of contents. It need not adhere to the structured format.

    Text

    The body of the manuscript should consist of the following sections in this order: 1) Introduction, 2) Materials and Methods, 3) Results, 4) Conclusions.

    Ethical Considerations in the Conduct and Reporting of Research:

    Protection of Human Subjects and Animals in Research

     

    When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

    *This portion of the Instructions for Authors has been quoted directly from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit www.icmje.org/ethical_6protection.html

    Tables and Illustrations

    Prepare each table with its title on a separate page in Microsoft word.  Each table must stand alone and contain all necessary information in the legend. The table itself must be comprehensible independently from the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in a table, and tables should not contain data that can be supplied within one or two sentences in the text.

    Figures must be submitted as either TIFF or EPS files and labeled as Figure 1, Figure 2 and so on. Color figures and halftones must be at a minimum 300 DPI resolution.
    Color must be saved as CYMK. Black and white line drawings must be at a minimum 1200 DPI resolution.

    A list of figure legends should be supplied at the end of the manuscript, double-spaced in Microsoft word. Magnifications should be included when appropriate. Illustrations can be printed in color with a subsidy from the author and are encouraged. Contact the publisher for details.

    Disclosure Statement

    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.

    If no conflicts exist, the authors must state “No competing financial interests exist."

    When naming your figure files, please label them with your manuscript number, followed by a period (.), and then list the figure number.  Ex:  MET-2008-0123.Fig1.  Label figures and tables inside the files in addition to naming the file with the figure or table number.  (ie:  When figures or table files are opened, the figure or table number should appear inside the file.)

    IMPORTANT:

    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper.  Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    If no conflicts exist, the authors must state “No competing financial interests exist."

    References

    References should be presented using the order of citation method. Please place a numerical superior in the text that corresponds to the number in the reference list. Below are examples of references in the reference list:

    Journal articles

     

    Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R.K., Alitalo K., Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997; 276: 1423-5

     

    Book chapters Ferrara N., Gerber H., The Vascular Endothelial Growth Factor Family. In: Ware J.A., Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 101-27.

     

    Please list each author’s name in the citation. If it is necessary to cite an abstract, this should be designated. Abbreviations of journal titles should follow Medline. Authors are responsible for the accuracy of the reference. Only works referred to in the text and already accepted for publication can be included.

    Permissions

    The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure or legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material and should accompany the manuscript.

    Reprints

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Publisher

    Lymphatic Research and Biology is published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; fax: (914) 740–2101.; E-mail: info@liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Cancer Biotherapy and Radiopharmaceuticals

    Cancer Biotherapy and Radiopharmaceuticals

    The established journal with over 25 years of peer-reviewed papers on new and innovative investigations of methods to improve cancer therapy. The Journal focuses on advancements in radioimmunotherapy and radiopharmaceuticals.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

Browse All Publications »